Initial Statement of Beneficial Ownership (3)
September 10 2021 - 7:05PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Lillis Charles M. |
2. Date of Event Requiring Statement (MM/DD/YYYY)
9/1/2021
|
3. Issuer Name and Ticker or Trading Symbol
SomaLogic, Inc. [SLGCW]
|
(Last)
(First)
(Middle)
C/O SOMALOGIC, INC., 2945 WILDERNESS PLACE, |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Street)
BOULDER, CO 80301
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Class A Common Stock, par value $0.0001 (1) | 276573 | D | |
Class A Common Stock, par value $0.0001 (1) | 100572 | I | See Footnote (2) |
Class A Common Stock, par value $0.0001 (1) | 12571 | I | See Footnote (3) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Employee Stock Option (Right to Buy) | (4) | 2/18/2031 | Class A Common Stock, par value $0.0001 | 20952 (5) | $4.7728 | D | |
Explanation of Responses: |
(1) | In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II, Inc. or "CMLS") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of SomaLogic Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock. |
(2) | Reflects stock held of record by The Lillis Foundation. Mr. Lillis may be deemed to be a beneficial owner of the shares held directly by The Lillis Foundation as a result of Mr. Lillis' voting and dispositive power with respect to the shares. |
(3) | Reflects stock held of record by CAG LLC. Mr. Lillis may be deemed to be a beneficial owner of the shares held directly by The Lillis Foundation as a result of Mr. Lillis' voting and dispositive power with respect to the shares. |
(4) | The shares underlying the option vest in 12 equal monthly installments starting on the 1st of the first full month following the date of the grant. |
(5) | In connection with the Closing, each outstanding SomaLogic equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the SomaLogic equity awards. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Lillis Charles M. C/O SOMALOGIC, INC. 2945 WILDERNESS PLACE, BOULDER, CO 80301 | X |
|
|
|
Signatures
|
/s/ Ruben Gutierrez, Attorney-in-Fact | | 9/10/2021 |
**Signature of Reporting Person | Date |
CM Life Sciences II (NASDAQ:CMII)
Historical Stock Chart
From Jun 2024 to Jul 2024
CM Life Sciences II (NASDAQ:CMII)
Historical Stock Chart
From Jul 2023 to Jul 2024